The Medical Letter on Drugs and Therapeutics
Erlotinib (Tarceva) for Advanced Non-Small Cell Lung Cancer
March 28, 2005 (Issue: 1205)Erlotinib (Tarceva) is the second oral epidermal growth factor receptor (EGFR) inhibitor to become available in the US for treatment of advanced refractory NSCLC. In clinical trials, erlotinib produced a response rate of only 8.9%, but increased...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.